Renal Cancer Clinical Quality Performance Indicators: Engagement Document

This document is being circulated for comment and feedback in order to ensure wide

engagement with professional groups, health service staff, voluntary organisations, patients affected by renal cancer and the wider public.

12. References

1. Scottish Government (2008). Better Cancer Care: An Action Plan [online]. Available from: (accessed August 2013).

2. Scottish Government (2010). 'Healthcare Quality Strategy for NHSScotland [online]. Available from: (accessed August 2013).

3. Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium (2010). AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J. 182(18), E839-E842 [online]. Available from: (accessed August 2013).

4. Macmillan Cancer Support (2013). Cancer Information - Kidney Cancer [online]. Available from: (accessed August 2013).

5. American Urological Association (2009). Guideline for management of the clinical stage 1 renal mass.

6. European Association of Urology (2014). Guideline on Renal Carcinoma [online]. Available from:

7. Dutch Association of Comprehensive Cancer Centres (2007). Renal cell carcinoma (English version) [online]. Available from: (accessed August 2013).

8. NHS Quality Improvement Scotland (2008). Management of Core Cancer Services Standards [online]. Available from: (accessed August 2013).

9. National Institute for Health and Clinical Excellence (2002). Improving outcomes in urological cancers: The manual (guidance on cancer services) [online]. Available from: (accessed August 2013)

10. Martin P, et al (2011). External Validation of the Leibovich Prognosis Score for Non metastatic Clear Cell Renal Cell Carcinoma at a Single European Center Applying Routine Pathology. The Journal of Urology ;186 (5): 1773 - 1778

11. Abouassaly R et al (2012). Volume-outcome relationships in the treatment of renal tumours. The Journal of Urology 187(6): 1984-8

12. Zargar H, et al (2015). Minimally invasive partial nephrectomy in the age of the 'trifecta'. British Journal of Urology International; 116(4): 505-6

13. Thompson AM, Stonebridge PA (2005). Building a framework for trust: critical event analysis of deaths in surgical care. BMJ. 330: 1139-42.

14. Heng. D et al (2013). External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. The Lancet Oncology. 2013; 14(2): 141-148. Available from: (Accessed April 2016)

15. National Institute for Health and Clinical Excellence (2009). Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma ( TA169) [online]. Available from: (accessed August 2013).

16. National Institute for Health and Clinical Excellence (2011). Pazopanib for the first-line treatment of advanced renal cell carcinoma ( TA215) [online]. Available from: (accessed August 2013)

17. Scottish Medicines Consortium (2011). Pazopanib 200mg, SMC 676/11 [online]. Available from: (accessed August 2013).


Back to top